SCHEMBL3536889

SCHEMBL3536889

c1cc(N2CCOCC2)c2[nH]c(-c3n[nH]c4ccccc34)nc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 8/20 0.72
FLT1 P17948 7/20 0.65
ITK Q08881 3/20 0.52
LRRK2 Q5S007 3/20 0.49
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
MAPK10 P53779 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ABL1 P00519 2/20 0.46
CLK2 P49760 2/20 0.45
DYRK1A Q13627 2/20 0.45
CLK3 P49761 1/20 0.45
NCF1 P14598 2/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3533364 0.78 FGFR1 (0.85) FGFR1FLT1ITKLRRK2ABL1
SCHEMBL30222327 0.76 FGFR1 (0.68) FGFR1FLT1ITKKDM4EALDH1A1
SCHEMBL5952268 0.74 FGFR1 (0.67) FGFR1FLT1ITKKDM4EALDH1A1
SCHEMBL5866739 0.74 FGFR1 (0.64) FGFR1FLT1ITKLRRK2ABL1
SCHEMBL311148 0.72 FGFR1 (1.00) FGFR1FLT1ITKKDM4EALDH1A1
SCHEMBL29714859 0.72 FGFR1 (1.00) FGFR1FLT1ITKKDM4EALDH1A1
SCHEMBL29548155 0.72 LRRK2 (0.72) FGFR1FLT1ITKLRRK2KDM4E
SCHEMBL26911852 0.72 LRRK2 (0.72) FGFR1FLT1ITKLRRK2KDM4E
SCHEMBL146694 0.71 KDM4E (0.53) FGFR1KDM4EMEN1ALDH1A1LMNA
SCHEMBL4920662 0.71 FGFR1 (0.60) FGFR1FLT1ITKKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885ITK 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.